Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.67 |
| ▸ | IGF1R | P08069 | 2/20 | 0.67 |
| ▸ | CDK4 | P11802 | 5/20 | 0.65 |
| ▸ | CDK1 | P06493 | 3/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684949 | 0.88 | CDK2 (0.64) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL17943211 | 0.87 | CDK2 (0.77) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL1684757 | 0.85 | CDK2 (0.71) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL27637599 | 0.85 | CDK2 (0.78) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL1684597 | 0.84 | DYRK1A (0.63) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL1684661 | 0.84 | CDK2 (0.67) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL1684922 | 0.83 | CDK2 (0.65) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL1684872 | 0.83 | CDK2 (0.70) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL27556467 | 0.83 | CDK2 (0.81) | CDK2IGF1RCDK4CDK1DYRK1A | |
| SCHEMBL23241872 | 0.81 | CDK2 (0.72) | CDK2IGF1RCDK4CDK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | CDK2 1442/4885IGF1R 1957/4885CDK4 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.